UBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $214
UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and lowers the price target from $231 to $214.
Share
Why It Matters
An expert analyst still likes Neurocrine but thinks it might be worth less money. This means the company is okay, but its stock price might come down a bit.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.